Primary endocrine resistance can be assessed by a diminished or absent proliferative BC response to short-term pET, as evidenced by in situ detection of the proliferation-associated nuclear Ki67 antigen (9, 12, 25). The gene discussed is MKI67; the disease is breast cancer.